[In vitro study of the cefamandole-fosfomycin combination against methicillin-resistant staphylococci].
In vitro antibacterial activity of cefamandole-fosfomycin (CFM-FOS) combination was studied on 50 methicillin-resistant staphylococci strains. Anti-bacterial effects were evaluated with a bactericidal microtiter checkerboard method. CFM-FOS was compared with other combinations known to be potent against staphylococci. Synergy was consistently recorded with CFM-FOS. Mean MBC of CFM combined with FOS was 1 microgram/ml. Vancomycin-fosfomycin combination was infrequently synergistic (20%). Rifampin-fosfomycin, cefamandole-fusidic acid, and cloxacillin-fusidic acid combinations were usually antagonistic at bactericidal levels. Rifampicin-fusidic acid combination usually yielded additive effects. CFM-FOS killed most methicillin-resistant staphylococci studied at therapeutic concentrations.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001770:Blood Bactericidal Activity; D002435:Cefamandole / Q000494:pharmacology*; D004338:Drug Combinations; D004357:Drug Synergism; D005578:Fosfomycin / Q000494:pharmacology*; D008712:Methicillin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D013210:Staphylococcus / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005578:Fosfomycin; D002435:Cefamandole; D008712:Methicillin
Etude in vitro de l'association céfamandole-fosfomycine vis-à-vis de souches cliniques de staphylocoques méthicilline-résistants.